INTEG B Stock Overview
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Integrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr51.40 |
| 52 Week High | kr64.00 |
| 52 Week Low | kr16.40 |
| Beta | 1.7 |
| 1 Month Change | 1.98% |
| 3 Month Change | 9.36% |
| 1 Year Change | 84.89% |
| 3 Year Change | -4.81% |
| 5 Year Change | 466.08% |
| Change since IPO | 128.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| INTEG B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | -10.1% | 3.3% | -0.7% |
| 1Y | 84.9% | -61.4% | 4.4% |
Price Volatility
| INTEG B volatility | |
|---|---|
| INTEG B Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: INTEG B has not had significant price volatility in the past 3 months.
Volatility Over Time: INTEG B's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1962 | 34 | Rickard Branemark | www.integrum.se |
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads.
Integrum AB (publ) Fundamentals Summary
| INTEG B fundamental statistics | |
|---|---|
| Market cap | kr947.57m |
| Earnings (TTM) | -kr4.20m |
| Revenue (TTM) | kr100.35m |
9.4x
P/S Ratio-225.6x
P/E RatioIs INTEG B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INTEG B income statement (TTM) | |
|---|---|
| Revenue | kr100.35m |
| Cost of Revenue | kr16.86m |
| Gross Profit | kr83.49m |
| Other Expenses | kr87.69m |
| Earnings | -kr4.20m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 83.20% |
| Net Profit Margin | -4.19% |
| Debt/Equity Ratio | 0% |
How did INTEG B perform over the long term?
See historical performance and comparison